Danielle Brill
Stock Analyst at Truist Securities
(3.77)
# 739
Out of 5,143 analysts
96
Total ratings
45.35%
Success rate
11.18%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TECX Tectonic Therapeutic | Maintains: Buy | $64 → $60 | $18.81 | +219.06% | 3 | Jan 8, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $172 → $169 | $135.41 | +24.81% | 8 | Jan 8, 2026 | |
| IMVT Immunovant | Maintains: Hold | $16 → $22 | $26.02 | -15.45% | 6 | Jan 8, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $48 → $45 | $36.69 | +22.65% | 9 | Jan 8, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $56 → $63 | $48.03 | +31.17% | 2 | Jan 8, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $30 → $33 | $23.23 | +42.06% | 2 | Jan 8, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $80 → $86 | $78.15 | +10.04% | 3 | Jan 8, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $535 → $530 | $365.46 | +45.02% | 3 | Jan 8, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $105 → $190 | $93.92 | +102.30% | 4 | Dec 16, 2025 | |
| IRON Disc Medicine | Maintains: Buy | $86 → $114 | $74.89 | +52.22% | 7 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $31.59 | +48.78% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $461.14 | - | 3 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $22.29 | +7.67% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $21.74 | +139.19% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $18.60 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $56.77 | +39.16% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $15.02 | +19.84% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $21.37 | +601.92% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $172.62 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $816.37 | -25.89% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $26.76 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $41.00 | +21.95% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $27.17 | +87.71% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $12.32 | +711.69% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $75.56 | - | 9 | Sep 18, 2023 |
Tectonic Therapeutic
Jan 8, 2026
Maintains: Buy
Price Target: $64 → $60
Current: $18.81
Upside: +219.06%
Neurocrine Biosciences
Jan 8, 2026
Maintains: Buy
Price Target: $172 → $169
Current: $135.41
Upside: +24.81%
Immunovant
Jan 8, 2026
Maintains: Hold
Price Target: $16 → $22
Current: $26.02
Upside: -15.45%
Harmony Biosciences Holdings
Jan 8, 2026
Maintains: Buy
Price Target: $48 → $45
Current: $36.69
Upside: +22.65%
Dianthus Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $56 → $63
Current: $48.03
Upside: +31.17%
Centessa Pharmaceuticals
Jan 8, 2026
Maintains: Buy
Price Target: $30 → $33
Current: $23.23
Upside: +42.06%
BridgeBio Pharma
Jan 8, 2026
Maintains: Buy
Price Target: $80 → $86
Current: $78.15
Upside: +10.04%
Alnylam Pharmaceuticals
Jan 8, 2026
Maintains: Buy
Price Target: $535 → $530
Current: $365.46
Upside: +45.02%
Palvella Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $105 → $190
Current: $93.92
Upside: +102.30%
Disc Medicine
Nov 10, 2025
Maintains: Buy
Price Target: $86 → $114
Current: $74.89
Upside: +52.22%
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $31.59
Upside: +48.78%
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $461.14
Upside: -
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $22.29
Upside: +7.67%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $21.74
Upside: +139.19%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $18.60
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $56.77
Upside: +39.16%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $15.02
Upside: +19.84%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $21.37
Upside: +601.92%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $172.62
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $816.37
Upside: -25.89%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $26.76
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $41.00
Upside: +21.95%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $27.17
Upside: +87.71%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $12.32
Upside: +711.69%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $75.56
Upside: -